Literature DB >> 18606544

Pyrrolidinyl pyridone and pyrazinone analogues as potent inhibitors of prolyl oligopeptidase (POP).

Curt D Haffner1, Caroline J Diaz, Aaron B Miller, Robert A Reid, Kevin P Madauss, Annie Hassell, Mary H Hanlon, David J T Porter, J David Becherer, Luke H Carter.   

Abstract

We report the synthesis and in vitro activity of a series of novel pyrrolidinyl pyridones and pyrazinones as potent inhibitors of prolyl oligopeptidase (POP). Within this series, compound 39 was co-crystallized within the catalytic site of a human chimeric POP protein which provided a more detailed understanding of how these inhibitors interacted with the key residues within the catalytic pocket.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18606544     DOI: 10.1016/j.bmcl.2008.06.067

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  8 in total

1.  Identification of novel Trypanosoma cruzi prolyl oligopeptidase inhibitors by structure-based virtual screening.

Authors:  Hugo de Almeida; Vincent Leroux; Flávia Nader Motta; Philippe Grellier; Bernard Maigret; Jaime M Santana; Izabela Marques Dourado Bastos
Journal:  J Comput Aided Mol Des       Date:  2016-10-21       Impact factor: 3.686

2.  Crystal Structure and Conformational Dynamics of Pyrococcus furiosus Prolyl Oligopeptidase.

Authors:  Ken Ellis-Guardiola; Huan Rui; Ryan L Beckner; Poonam Srivastava; Narayanasami Sukumar; Benoît Roux; Jared C Lewis
Journal:  Biochemistry       Date:  2019-03-05       Impact factor: 3.162

3.  Metal-free [3 + 2 + 1]/[2 + 2 + 1] biscyclization: stereospecific construction with concomitant functionalization of indolizin-5(1H)-one.

Authors:  Tuan-Jie Li; Zhong-Qiu Liu; Hong-Mei Yin; Chang-Sheng Yao; Bo Jiang; Xiang-Shan Wang; Shu-Jiang Tu; Xiu-Ling Li; Guigen Li
Journal:  J Org Chem       Date:  2013-11-07       Impact factor: 4.354

4.  Structural analysis of prolyl oligopeptidases using molecular docking and dynamics: insights into conformational changes and ligand binding.

Authors:  Swati Kaushik; Ramanathan Sowdhamini
Journal:  PLoS One       Date:  2011-11-23       Impact factor: 3.240

Review 5.  Parasite prolyl oligopeptidases and the challenge of designing chemotherapeuticals for Chagas disease, leishmaniasis and African trypanosomiasis.

Authors:  I M D Bastos; F N Motta; P Grellier; J M Santana
Journal:  Curr Med Chem       Date:  2013       Impact factor: 4.530

6.  Therapeutic Effect of Novel Cyanopyrrolidine-Based Prolyl Oligopeptidase Inhibitors in Rat Models of Amnesia.

Authors:  Nikolay N Zolotov; Igor A Schepetkin; Tatyana A Voronina; Vladimir F Pozdnev; Andrei I Khlebnikov; Irina V Krylova; Mark T Quinn
Journal:  Front Chem       Date:  2021-12-22       Impact factor: 5.221

7.  Crystal structures of Trypanosoma brucei oligopeptidase B broaden the paradigm of catalytic regulation in prolyl oligopeptidase family enzymes.

Authors:  Peter Canning; Dean Rea; Rory E Morty; Vilmos Fülöp
Journal:  PLoS One       Date:  2013-11-12       Impact factor: 3.240

8.  New compounds identified through in silico approaches reduce the α-synuclein expression by inhibiting prolyl oligopeptidase in vitro.

Authors:  Raj Kumar; Rohit Bavi; Min Gi Jo; Venkatesh Arulalapperumal; Ayoung Baek; Shailima Rampogu; Myeong Ok Kim; Keun Woo Lee
Journal:  Sci Rep       Date:  2017-09-07       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.